RxDoctor Payments Data

Kshama Keshava Bhat, MD

Family Medicine · Milwaukee, WINPI 1255526190

Payments from drug & device makers

$4,247in general payments, 2019–2025

Across 206 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$605
  • Lilly USA, LLC$375
  • Bayer$206
  • Pfizer$190
  • Exact Sciences$180
  • plus $789 from 22 others

What the payments were for

  • Food & beverage$4,05495%
  • Education$1945%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,247 in reported general payments places this provider in the 95th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$44,886
Medicare patients
86
Services billed
482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide189$239,223
LinzessLinaclotide71$83,189
WegovySemaglutide31$42,135
JardianceEmpagliflozin23$37,275
EliquisApixaban29$33,739
Breo ElliptaFluticasone/Vilanterol38$33,010
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$21,400
MyrbetriqMirabegron17$15,520
MounjaroTirzepatide13$13,837
EntrestoSacubitril/Valsartan12$13,059
TrulancePlecanatide12$11,190
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,972
Albuterol Sulfate HfaAlbuterol Sulfate101$3,559
Omeprazole117$2,970
Levothyroxine Sodium250$2,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$1,903$281,357220 claims
AbbVieLinzess$106$83,18971 claims
GSKBreo Ellipta, Trelegy Ellipta$57$54,41057 claims
Boehringer IngelheimJardiance$15$37,27523 claims
PfizerEliquis$190$33,73929 claims
Astellas Pharma US IncMyrbetriq$67$15,52017 claims
Lilly USA, LLCMounjaro$375$13,83713 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$14$11,19012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →